Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZED1227 in NAFLD with significant fibrosis
NCT05305599Phase 2Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Apr 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ZED1227 in non-alcoholic fatty liver disease (NAFLD), sponsored by Dr. Falk Pharma GmbH. Started Apr 2022; status: completed.
02
Drugs
ZED1227
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT05305599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05305599.